Showing 1,881 - 1,900 results of 41,796 for search '(( 50 ((ng decrease) OR (mean decrease)) ) OR ( 16 ((teer decrease) OR (a decrease)) ))', query time: 1.04s Refine Results
  1. 1881

    Longitudinal Lung Function Decrease in Subjects with Spontaneous Healed Pulmonary Tuberculosis by Seung Heon Lee (713097)

    Published 2016
    “…</p><p>Results</p><p>At baseline, there were no differences in gender, smoking amount, and mean height, except mean age (50.0 ± 8.1 VS. 48.1 ± 7.3, <i>P</i>< 0.001) between the SHPTB and normal group. 52% of the 339 participants with SHPTB and 56% of the 3211 normal participants participated till the end of study. …”
  2. 1882
  3. 1883
  4. 1884

    Data Sheet 1_Pan-cancer analysis reveals TRA16 as a master regulator of human carcinogenesis.pdf by Yanyan Zhu (32035)

    Published 2025
    “…</p>Methods<p>We conducted a comprehensive pan-cancer analysis of TRA16 expression and function across multiple human malignancies. …”
  5. 1885
  6. 1886

    Table1_METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma.DOCX by Liting Lu (217760)

    Published 2022
    “…METTL16, an m<sup>6</sup>A“writer,” was chosen as a unique candidate of PDA, owing to its markedly differential expression under mutations of all driver genes (KRAS, TP53, CDKN2A, and SMAD4) and its favorable prognostic value. …”
  7. 1887

    Image1_METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma.pdf by Liting Lu (217760)

    Published 2022
    “…METTL16, an m<sup>6</sup>A“writer,” was chosen as a unique candidate of PDA, owing to its markedly differential expression under mutations of all driver genes (KRAS, TP53, CDKN2A, and SMAD4) and its favorable prognostic value. …”
  8. 1888

    Table2_METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma.DOCX by Liting Lu (217760)

    Published 2022
    “…METTL16, an m<sup>6</sup>A“writer,” was chosen as a unique candidate of PDA, owing to its markedly differential expression under mutations of all driver genes (KRAS, TP53, CDKN2A, and SMAD4) and its favorable prognostic value. …”
  9. 1889
  10. 1890
  11. 1891
  12. 1892
  13. 1893
  14. 1894
  15. 1895
  16. 1896
  17. 1897
  18. 1898

    Fig 7 - by Finn Egil Skjeldestad (7821716)

    Published 2024
    Subjects:
  19. 1899
  20. 1900